A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.

Inclusion Criteria: * Diagnosis of schizophrenia present for at least 1 year, and has not returned to his/her level of functioning before the disease, with a Brief Psychiatric Rating Scale score of 30 to 60 (inclusive), and cognitive impairment as determined by scores from neuropsychological tests and subtests * Nicotine user with a minimum intake equivalent to 5 cigarettes per day * On a stable dose of allowed atypical antipsychotic medication (risperidone \[either oral or CONSTA\], olanzapine, quetiapine, ziprasidone, or aripiprazole) alone or in combination, for at least 30 days before screening, and deemed able to continue on the same dose * Women patients must be postmenopausal, surgically sterile, or using appropriate contraception before entry and throughout the study, and have a negative pregnancy test at screening * Able to read, write, and understand English, and has no limitations in communication skills that would prevent him/her from completing the cognitive tests used in this study. Exclusion Criteria: * Previously enrolled in a galantamine hydrobromide study * Any clinically significant uncontrolled medical illness (such as peptic ulcer disease * urinary tract obstruction * or neurologic, cardiac, hepatic, renal, metabolic, or endocrine disturbances) * History of severe asthma * Any history of epilepsy or convulsions, except for febrile convulsions during childhood * History of cancer within the past year, except for treated basal cell carcinoma, or any hist…